|
Impact of immunohistochemical staining, IHC expressed (+ve) and those that did not express IHC markers (-ve), for Chromogranin A and neuron specific enolase on overall and cause specific survival |
||||||
| CgA+ve |
CgA-ve |
p-value |
NSE +ve |
NSE -ve |
p value |
|
|
|
||||||
| Overall expression (n, %) |
30, 36% |
54, 64% |
0.005 |
44,48% |
40,52% |
0.22 |
|
|
||||||
| Overall survival (n, %) |
5, 17% |
45, 83% |
0.001 |
24,55% |
26,65% |
0.32 |
|
|
||||||
| Cancer specific survival (n, %) |
4, 13% |
41, 76% |
0.004 |
21,48% |
24,60% |
0.30 |
|
|
||||||
| Metastatic disease (n, %) |
18, 60% |
17, 32% |
0.002 |
19,43% |
16,40% |
0.24 |
|
CgA: Chromogranin A NSE: Neuron specific enolase | ||||||
Ather et al. BMC Urology 2008 8:21 doi:10.1186/1471-2490-8-21 |
||||||